ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• One Day, We Won't Need Placebos

  Embrace the future of clinical research by recognizing the limitations of traditional double-blind trials and exploring the transformative potential of real-world evidence (RWE).

• Oncology Preferences From Patients And Caregivers On Trial Tech

  Delve into the preferences of patients and caregivers in the field of oncology, specifically regarding eConsent, telehealth, wearables, and other digital technologies.

• Advancing Neuromuscular Research with Digital Endpoints

  Explore cutting-edge digital measures that capture peak mobility and activity in real-world settings, offering meaningful insights into disease progression in neuromuscular disorders.

• Nevro Eliminates Majority Of Source Data Verification With ePRO And EDC

  Read how a global medical device company was able to unlock new efficiencies by implementing data collection via electronic patient-reported outcome assessments.

• Fujirebio Increases Study Agility By Streamlining Clinical Operations And Data Management Process

  Fujirebio’s fast-growing U.S. Clinical R&D team was preparing for shorter studies with higher complexity. Traditional methods using paper and spreadsheet trackers were no longer adequate to meet quality goals. Learn how the group increased its agility and readiness with LifeSphere Clinical EDC and CTMS tools.

• eCOA In Oncology Trials: A Tool To Simplify

  Accurate quality of life data is critical in oncology. eCOA unified with IRT streamlines trials, improves data collection, and enhances site user experiences across therapeutic areas.

• Considerations When Selecting An Interactive Response Technology Provider

  Interactive response technology (IRT) systems ensure clinical trial participants receive the correct treatment, facilitate enhanced logistics tracking, and empower users to obtain real-time data.

• Clinical Trials In The Age Of Cost Caps

  On February 7, 2025, the NIH introduced a pivotal policy (NOT-OD-25-068), capping indirect cost recovery at 15% for research grants.

• The Case For Cognitive Assessments In Phase 1 Clinical Trials

  Regulators prioritize patient-reported outcomes. Cognitive assessments in Phase 1 trials detect early drug-related cognitive effects, ensuring safety and efficacy. Signant’s CDR System® is a proven tool for this.

• 7 Key Considerations For Designing The Optimal IRT/RTSM

  Sponsors can create IRT/RTSM systems that are not only efficient and reliable but also adaptable to the evolving needs of clinical research by focusing on these seven key considerations.